Troriluzole

Troriluzole is an experimental medication that has been investigated as a potential treatment for Machado–Joseph disease (MJD), obsessive–compulsive disorder (OCD), , spinocerebellar ataxia (SCA), and glioblastoma.

Uses your system voice; voice and rate in settings.

Snapshot

≈ 1 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Troriluzole is an experimental medication that has been investigated as a potential treatment for Machado–Joseph disease (MJD), obsessive–compulsive disorder (OCD), , spinocerebellar ataxia (SCA), and glioblastoma. It is a prodrug modification of the medication riluzole.

Pharmacokinetics

While riluzole is typically taken twice-daily and on an empty stomach, troriluzole may offer a potential once-daily dosing with or without food along with greater bioavailability.

Research

In 2024, researchers published a study in the Journal of Neurochemistry that reported troriluzole could reverse some early Alzheimer's disease brain changes in mice, reduce harmful glutamate levels, and improve memory and learning abilities.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1371289850 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

3 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.